Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 312

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 2
Chunk 312
---
 Loss from operations 
     (14,036,901) 
     (14,102,545) 
     65,644  
     (0.5)%

    Other income (expense): 

    Gain from settlement of liabilities with vendor 
     -  
     589,223  
     (589,223) 
     (100.0)%
  
    Other income (expenses) 
     248  
     (630,922) 
     631,170  
     (100.0)%
  
    Change in fair value of earnout and derivative liabilities 
     -  
     5,190,117  
     (5,190,117) 
     (100.0)%
  
    Share-based inducement expense 
     (863,550) 
     -  
     (863,550) 
     (100.0)%
  
    Write off of deferred offering costs 
     (500,000) 
     -  
     (500,000) 
     (100.0)%
  
    Interest income (expense), net 
     20,562  
     (22,188) 
     42,750  
     192.7%
  
    Total other income (expense), net 
     (1,342,740) 
     5,126,230  
     (6,468,970) 
     (126.2)%
  
    Net loss 
     (15,379,641) 
     (8,976,315) 
     (6,403,326) 
     71.3%
  
    Deemed dividend on Series A, B and C Preferred Stock 
     (24,964,518) 
     -  
     (24,964,518) 
     100%
  
    Deemed dividend on Series D Preferred Stock 
     (6,649,828) 
     -  
     (6,649,828) 
     100%
  
    Deemed dividend related to Series C Common Warrants 
     (84,083) 
     -  
     (84,083) 
     100%
  
    Net loss attributable to common stockholders 
    $(47,078,070) 
    $(8,976